Swarna Bale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Swarna Bale has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anjana Yeldandi
Department of Pathology, Feinberg School of Medicine Northwestern University, 676 North St. Clair Street, Chicago, IL 60611, USA
1 shared publication - Craig Horbinski
Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, USA
1 shared publication - Dan Xu
Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
1 shared publication - Daniel Procissi
Department of Radiology, Feinberg School of Medicine, Northwestern University Chicago, IL, USA
1 shared publication - Igal Ifergan
Department of Molecular and Cellular Biology, College of Medicine, University of Cincinnati, Cincinnati, OH USA
1 shared publication - John Varga
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, USA
1 shared publication
Latest Publications
- Open Access
- 8 March 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (5)
PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis
Systemic sclerosis (SSc) is a chronic, multisystem orphan disease with a highly variable clinical course, high mortality rate, and a poorly understood complex pathogenesis. We have identified an important role for a subpopulation of monocytes and macrophages characterized by surface expression of the scavenger receptor macrophage receptor with collagenous structure (MARCO) in chronic inflammation and fibrosis in SSc and in preclinical disease models. We show that MARCO + monocytes and macrophages accumulate in lesional skin and lung in topographic proximity to activated myofibroblasts in patients with SSc and in the bleomycin-induced mouse model of SSc. Short-term treatment of mice with a potentially novel nanoparticle, poly(lactic- co -glycolic) acid (PLG), which is composed of a carboxylated, FDA-approved, biodegradable polymer and modulates activation and trafficking of MARCO + inflammatory monocytes, markedly attenuated bleomycin-induced skin and lung inflammation and fibrosis. Mechanistically, in isolated cells in culture, PLG nanoparticles inhibited TGF-dependent fibrotic responses in vitro. Thus, MARCO + monocytes are potent effector cells of skin and lung fibrosis and can be therapeutically targeted in SSc using PLG nanoparticles.
- 8 March 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (5)
Open AccessPLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis
Systemic sclerosis (SSc) is a chronic, multisystem orphan disease with a highly variable clinical course, high mortality rate, and a poorly understood complex pathogenesis. We have identified an important role for a subpopulation of monocytes and macrophages characterized by surface expression of the scavenger receptor macrophage receptor with collagenous structure (MARCO) in chronic inflammation and fibrosis in SSc and in preclinical disease models. We show that MARCO + monocytes and macrophages accumulate in lesional skin and lung in topographic proximity to activated myofibroblasts in patients with SSc and in the bleomycin-induced mouse model of SSc. Short-term treatment of mice with a potentially novel nanoparticle, poly(lactic- co -glycolic) acid (PLG), which is composed of a carboxylated, FDA-approved, biodegradable polymer and modulates activation and trafficking of MARCO + inflammatory monocytes, markedly attenuated bleomycin-induced skin and lung inflammation and fibrosis. Mechanistically, in isolated cells in culture, PLG nanoparticles inhibited TGF-dependent fibrotic responses in vitro. Thus, MARCO + monocytes are potent effector cells of skin and lung fibrosis and can be therapeutically targeted in SSc using PLG nanoparticles.